

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin

Shutaro Gunji¹, Kazukata Obama¹, Makoto Matsui², Yasuhiko Tabata², Yoshiharu Sakai¹

1 Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan

2 Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan

shutaro@kuhp.kyoto-u.ac.jp

Tel: +81-75-751-4108

Fax: +81-75-751-4646

1 **ABSTRACT**

2
3 **Background:** Peritoneal carcinomatosis is a poor prognostic factor for patients with gastrointestinal,
4 gynecologic, and pancreatic cancer. Cisplatin (CDDP) is one of the most effective anti-cancer agents,
5 although its adverse effects still remain unresolved. For the treatment of peritoneal carcinomatosis with
6 high-dose CDDP, it is necessary to design a new delivery system of CDDP that can decrease systemic
7 toxicity and achieve a more targeted high-dose chemotherapy.

8
9 **Methods:** Microspheres were prepared from gelatin of a non-toxic and biodegradable material for the
10 sustained release of CDDP. The gelatin microspheres incorporating CDDP (GM-CDDP) were injected
11 intraperitoneally into a mouse model of peritoneal carcinomatosis; their therapeutic efficacy and adverse
12 effects were evaluated in comparison with intraperitoneal administration of free CDDP.

13
14 **Results:** GM-CDDP released CDDP in the peritoneal cavity as a result of gelatin biodegradation. The mice
15 treated with microspheres in the peritoneal cavity lived longer than mice treated with free CDDP (74±23
16 days vs. 40±23 days, p<0.05). The mice treated with GM-CDDP also lost no weight, while the free CDDP
17 group lost approximately 20% body weight (106±5% vs. 80±7%, p<0.001, body weight of day 1=100%).
18 GM-CDDP significantly decreased the nephrotoxicity and hematotoxicity of CDDP.

19
20 **Conclusions:** Gelatin microsphere decreased the adverse effects of CDDP and allowed high dose
21 intraperitoneal chemotherapy with the control of CDDP. This technique of gradual local release may allow
22 us to provide a high dose targeted intraperitoneal chemotherapy with CDDP, resulting in enhanced anti-
23 cancer effects. These gelatin microspheres may be useful as a drug carrier for the treatment of peritoneal
24 carcinomatosis.

25
26 **Key Words:** peritoneal carcinomatosis, intraperitoneal chemotherapy, drug delivery system, gelatin

1 **INTRODUCTION**

2
3 Peritoneal carcinomatosis is one of the most serious clinical problems often observed in patients with
4 colorectal, ovarian, gastric, pancreatic, and appendiceal carcinoma.¹ Peritoneal carcinomatosis generates
5 malignant ascites, multiple small cancer nodules, and tumor masses of various sizes. These events impair
6 the quality of life and lead to early mortality.¹ Metastatic dissemination in the peritoneal cavity is too
7 widespread and numerous to perform complete a resection of each tumor mass.² Moreover, microscopic
8 invasion of cancer cells was often observed in cases where no cancer nodules were observed
9 macroscopically. Therefore, it is very difficult to treat peritoneal recurrence of cancer, even if after a
10 complete macroscopic resection.

11 Intraperitoneal chemotherapy has been shown to achieve a high concentration of drugs in the peritoneal
12 cavity in various cancers. Intraperitoneal chemotherapy decreases adverse systemic effects by maximizing
13 the amount of drug delivered directly into the disseminated cancer cells.

14 Cisplatin (CDDP) is one of the most effective agents for gastrointestinal and gynecologic cancers.³⁻⁶
15 Because intraperitoneal administration of CDDP transfers into the blood circulation rapidly and the
16 retention time in the cancer tissue is very short, it is difficult to expect both high and prolonged anti-cancer
17 effects.⁷ Furthermore, due to the adverse systemic effects, such as nephrotoxicity, myelosuppression,
18 nausea, and emesis, oncologists have to decrease the administered dose or temporarily stop chemotherapy
19 with CDDP.

20 Recently, new drug delivery systems have been explored extensively to achieve greater concentrations of
21 drugs in the cancer tissue and their controlled release for extended time periods. Most research regarding
22 anti-cancer drugs with liposomes,^{8,9} polymeric micelles,¹⁰ and microspheres¹¹⁻¹³ have designed the drug
23 delivery based on the enhanced permeability retention effect using intravenous administration to target the
24 cancer tissue,¹⁴ but, such approaches are not always suitable for the treatment because of less intratumoral
25 concentration of drugs and their concerns about systemic biosafety for clinical use. Therefore, it is
26 important to design a novel CDDP delivery system to achieve high dose intraperitoneal chemotherapy to
27 decrease the adverse systemic effects.

28 In this study, biodegradable gelatin microspheres incorporating CDDP (GM-CDDP) were prepared to
29 achieve local controlled release of CDDP into the peritoneal cavity. Microspheres were prepared from
30 gelatin, a non-toxic, biodegradable material for sustained release of CDDP. After GM-CDDP with different
31 biodegradabilities was administered intraperitoneally to mice models of peritoneal carcinomatosis, their
32 therapeutic and adverse effects were evaluated.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

MATERIALS AND METHODS

Chemicals

A gelatin sample with an isoelectric point of 5.0 (molecular weight = 100,000) prepared by an alkaline process bovine bone and collagenase L were supplied by Nitta gelatin, Inc. (Osaka, Japan). Glutaraldehyde and glycine were purchased from Nacalai Tesque, Inc (Kyoto, Japan). Cisplatin was purchased from Nippon Kayaku Co., Ltd. (Tokyo, Japan). Tween 80 was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).

Animals

Seven-week-old, Balb/c male mice (20 g body weight) were purchased from Shimizu Laboratory Supplies Co., Ltd. (Kyoto, Japan) and maintained under pathogen-free conditions. The experimental treatment of animals followed the Helsinki Convention (medical), and this study protocol was approved by the Animal Experiment Committee of the Institute for Frontier Medical Sciences, Kyoto University.

Cancer cells

In our preliminary experiment, we chose the colon-26 cell line because it was sensitive to CDDP (data not shown). The cells were cultured in D-MEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 15 vol % fetal calf serum (FCS) (Thermo Inc., Waltham, USA), penicillin (50 U/ml), and streptomycin (50U/ml) and cultured at 37°C in a 95% air, 5% carbon dioxide atmosphere.

Preparation of GM-CDDP

Gelatin microspheres were prepared by chemical cross-linking of gelatin in a water-in-oil emulsion state according to the method reported previously.¹⁵ Briefly, an aqueous solution (20 ml) of 10 wt % gelatin was preheated at 40°C and then added dropwise into 600 ml of olive oil (Wako Ltd, Osaka, Japan) at 40°C, followed by stirring at 200 or 400 rpm for 10 min to prepare a water-in-oil emulsion. The emulsion temperature was decreased to 4 °C for the natural gelation of gelatin solution to develop into non-crosslinked gelatin microspheres.

The resulting microspheres were washed three times with cold acetone in combination with centrifugation (5,000 rpm, 4°C, 5 min) to completely exclude any residual oil. Then they were fractionated by size using sieves with apertures of 20, 32, and 75 μ m (Iida Seisakusho Co. Ltd., Osaka, Japan) and air-dried at 4°C. We prepared four types of gelatin microspheres, numbered Gel 1 to 4. The non-crosslinked and dried gelatin microspheres were placed in 0.1 wt % Tween 80 aqueous solution containing different amount of 25 wt % glutaraldehyde (20 μ l to Gel 1, 50 μ l to Gel 2, 100 μ l to Gel 3 and 4) and stirred for 4 h (Gel 3) and 24 h (Gel 1,2,and 4) to allow gelatin to crosslink. After collection by centrifugation (5,000 rpm, 4°C, 5 min), the microspheres were agitated in 10 mM aqueous glycine solution at 37°C for 1 h to block the residual aldehyde groups of unreacted glutaraldehyde. The resulting microspheres were finally washed three times with double-distilled water by centrifugation, and then freeze-dried.

1 The CDDP powder was dissolved in double-distilled water at a final concentration of 2 mg/ml to obtain
2 free CDDP solution. To prepare GM-CDDP, 50 μ l of free CDDP solution was added to 5 mg of freeze-dried
3 gelatin microspheres left for 24 h at 4°C.

4 5 **Characterization of gelatin microspheres**

6 Crosslinked gelatin microspheres were imaged using scanning electron microscopy (Model S-450,
7 Hitachi, Ltd. Tokyo, Japan) after platinum coating. The gelatin microspheres were also imaged using light
8 microscopy (CKX41, Olympus, Tokyo, Japan) in the dispersion state.

9 Microscopic photographs of gelatin hydrogel microspheres in the dried or water-swollen state were taken
10 to measure their size (100 microspheres per each sample) (Figures 1C & D). The water content of the
11 microspheres was computed based on the microsphere volume calculated from the size, which is defined as
12 the volume percentage of water to swollen gelatin hydrogel microspheres.¹⁶

13 14 **Evaluation of in vitro degradation of gelatin microspheres**

15 Gelatin microspheres (10 mg) were fully swollen in 750 μ l of double-distilled water for 12 h at 25°C,
16 then 750 μ l of 2N HCl aqueous solution was added and incubation took place at 25°C for various time
17 periods. The 25°C solution was centrifuged at 5,000 rpm for 5 min, while 200 μ l of supernatant was
18 collected. After that, 200 μ l of fresh, 1 N HCl aqueous solution was added and incubation at 25°C
19 continued. The absorbance of supernatant collected at 260 nm was measured by ultraviolet-visible
20 spectroscopy (DU@ 800 Spectrophotometer, Beckman Coulter, Inc., Fullerton, CA); and the amount of
21 gelatin degraded was calculated by combining a calibration curve prepared with the gelatin solution at
22 given concentrations.

23 24 **Evaluation of in vitro CDDP release from GM-CDDP**

25 GM-CDDP were placed in 10 ml of 0.01 mol/L phosphate-buffered saline solution (PBS, pH 7.4)
26 containing 0.01 wt % Tween 80, and the system was agitated reciprocally at 60 strokes/min in a water bath
27 at 37°C. At 1.5, 4, and 24 h, 5 ml of the supernatant was pipetted, and immediately after that, the same
28 volume of PBS was added. After 24 h, 500 μ l of 5 μ g/ml collagenase L solution was added to each sample.
29 The same collection was performed three times for 3 h.

30 To measure the CDDP concentration, we measured the platinum concentration of solutions sampled on a
31 polarized Zeeman Z-8000 atomic absorption spectrophotometer (Hitachi, Ltd. Tokyo, Japan).

32 33 **Preliminary evaluation of CDDP biodistribution in vivo**

34 Gelatin microspheres incorporating 40 μ g CDDP and 40 μ g free CDDP were injected intraperitoneally
35 into normal mice. Samples of blood, ascitic fluid, and kidney were collected 1.5, 4, 24, 48, and 168 h after
36 administration. At each time point, mice were sacrificed. Their blood was taken directly from the heart with
37 a heparinized syringe and centrifuged to obtain serum. Next, 5ml of PBS was injected intraperitoneally, a
38 peritoneal lavage was performed, and then the ascitic fluid was collected and centrifuged (9,000 rpm, room
39 temperature, 5 min). The platinum concentration of serum and lavage supernatant was measured with the

1 atomic absorption spectrophotometer. Kidneys were treated with 70 wt% nitric acid at 90°C for 2 h, the
2 supernatant was diluted ten times and centrifuged, and the platinum concentration of supernatant was
3 measured similarly.

4 5 **In vivo inhibitory effect of GM-CDDP for tumor development**

6 Colon-26 cells (1×10^6) were suspended in 1 ml of PBS and inoculated intraperitoneally to mice on Day
7 0. Then, on Day 1 and 4 after cancer inoculation, GM-CDDP or free CDDP were injected into the
8 peritoneal cavity of mice at the total administration dose of 10 mg cisplatin /kg body weight. As control
9 groups, gelatin microspheres alone (GM without CDDP) and PBS (non-treatment) were injected. In each
10 group, the number of the mice was 5. On Day 10, mice were euthanized and every tumor mass was resected
11 to measure their weight.

12 13 **Comparison of survival time and body weight change**

14 For comparison of survival time, we injected 20 mg CDDP/kg of GM-CDDP or free CDDP
15 intraperitoneally into each tumor-bearing mouse. In each group, the number of the mice was 6. Then the
16 survival time and body weight were evaluated daily after cancer inoculation. As a control group, gelatin
17 microspheres alone and PBS (non-treatment) were injected to the mice.

18 19 **Histologic observation of milky spots after gelatin microspheres administration in vivo**

20 The histologic cross-sections of the greater omentum of mice were made two days after intraperitoneal
21 administration of gelatin microspheres. The greater omentum was excised and fixed in 10 wt%
22 formaldehyde aqueous solution. A pathologist determined the location of milky spots macroscopically, and
23 prepared those cross-sections. The section was stained with hematoxylin-eosin to view on a light
24 microscopy.

25 26 **Animal tolerance study for GM-CDDP**

27 To examine the toxicity and tolerance for GM-CDDP comparing with free CDDP, normal mice were
28 injected with GM-CDDP or free CDDP at a dose of 5 mg CDDP/kg weekly. As control groups, gelatin
29 microspheres alone and PBS (non-treatment) were injected in the same way. In each group, the number of
30 the mice was 5. The body weights of the mice were measured weekly and expressed as a percentage of their
31 initial body weight. After five administrations, blood was taken from their hearts. The adverse effects of
32 CDDP administration were evaluated by body weight loss, the number of red blood cells (RBC) and white
33 blood cells (WBC), platelets (Plt), hemoglobin (Hb), and the serum concentrations of blood urea nitrogen
34 (BUN) and creatinine (Cr). The blood samples were analyzed by FALCO biosystems Ltd. (Kyoto, Japan).

35 36 **Statistical analysis**

37 All results are expressed as the mean \pm standard deviation (SD) and the data analyzed by using SPSS
38 6.1 software (Statistical Products and Service Solutions, Chicago, IL). Comparisons between two groups
39 were carried out using a two-tailed, Student's t test, and between multiple groups using one-way analysis of

1 variance (ANOVA) with Tukey's test of significance between individual groups. Survival analysis was
2 performed using the Kaplan-Meier method and analyzed by the log-rank test and Cox regression. $p < 0.05$
3 was considered to be significant.

4 5 **RESULTS**

6 7 **Characterization of gelatin microspheres**

8 Figures 1 shows the scanning electron micrographs of gelatin microspheres before (Figure 1A) and after
9 (Figure 1B) crosslinking. The microspheres of spherical shape and the surface were smooth before
10 crosslinking and freeze-drying (Figure 1A). A crosslinking changed the microstructures of the microspheres.
11 A porous structure was observed on the surface of microspheres. After addition of double-distilled water,
12 the microspheres swelled rapidly (Figures 1C and D).

13 14 **In vitro experiments of gelatin microspheres incorporating CDDP**

15 We prepared four types of gelatin microspheres, and the Gel 4 microspheres with greater crosslinking
16 showed less degradation. The other groups of microspheres degraded faster, although the degradation
17 profile was similar (see appendix, online version only). In the CDDP-releasing test, Gels 1, 2, and 3
18 microspheres showed similar release profiles, and the initial burst release was around 25 to 30%. Gel 4
19 microspheres showed a lesser initial burst in CDDP release, and they remained longer than those of the
20 other 3 gels. After addition of collagenase L, CDDP was released rapidly due to the degradation of gelatin
21 microspheres. Gel 4 microspheres also showed less release than those of others (see appendix, online
22 version only).

23 Based on these release data, Gel 4 microspheres were chosen for the following experiments because of
24 the longer CDDP release profile.

25 26 **CDDP biodistribution**

27 We examined the time profile of CDDP concentration in the ascitic fluid, serum, and kidney
28 parenchyma after the administration of GM-CDDP and free CDDP into mice (see appendix, online version
29 only). In the free CDDP group, the Pt level in the serum and ascites was much greater in the initial 4 h than
30 that of GM-CDDP as seen in PBS, and thereafter decreased rapidly. A high CDDP concentration was
31 detected in the kidney in the free CDDP group even one week after administration, while the CDDP
32 concentration remained at a lesser level in the GM-CDDP group. In contrast, the CDDP was detected in the
33 ascites over the range of 168 h in the GM-CDDP group, whereas it decreased rapidly in the free CDDP
34 group.

35 36 **Inhibitory effect of GM-CDDP for tumor development**

37 Figure 2A shows intraperitoneal appearance of Colon-26 tumor mass after intraperitoneal administration
38 of GM-CDDP (a), free CDDP (b), GM without CDDP (c), and PBS (non-treatment) (d). For the free CDDP
39 group, a few tumor nodules were detected in the abdominal cavity, but the intestinal wall was thinner and

1 edematous compared with that of the other groups. In the GM-CDDP groups, microspheres were still
2 observed along the greater omentum, subphrenic area, pouch of Douglas, and hepatic portal region, and no
3 gross tumor nodules were observed in the abdominal cavity. The tumor weights of GM-CDDP group, free
4 CDDP group, GM without CDDP and PBS group are 108 ± 1.45 mg, 151 ± 66.0 mg, 1070 ± 635 mg and
5 869 ± 452 mg respectively. The tumor weight was less in the GM-CDDP and free CDDP groups compared
6 with control groups ($p<0.001$). No statistical difference in the tumor weight was detected between the GM-
7 CDDP and free CDDP groups (Figure 2B).

8 9 **Survival time and body weight change**

10 Figure 3A shows the change of body weight in the 2 weeks after cancer inoculation and administration.
11 The administration of free CDDP decreased the body weight of mice, and the extent of body weight loss
12 was greater than that of the GM-CDDP group ($80\pm 7\%$ vs. $106\pm 5\%$, $p<0.001$, BW of day 1=100%). In the
13 both control groups, body weight loss was not observed.

14 Figure 3B shows the survival curve of cancer-bearing mice after the treatments. Even though free CDDP
15 demonstrated better survival time than both control groups, the administration of GM-CDDP showed a
16 prolonged survival time compared with that of free CDDP (74 ± 23 days vs. 40 ± 23 days, $p<0.05$).

17 18 **Animal tolerance study**

19 Figure 4A gives the time profile of body weight changes after the administration of GM-CDDP, free
20 CDDP, GM without CDDP, and PBS (non-treatment). The body weight of mice decreased gradually only in
21 the free CDDP group, whereas the GM-CDDP group and the two control groups did not show any decrease
22 in body weight. The serum BUN and Cr levels of the free CDDP group were significantly greater than
23 those of GM-CDDP group (BUN: 59 ± 12 mg/dl vs. 21 ± 2 mg/dl, $p<0.001$; Cr: 0.4 ± 0.1 mg/dl vs. 0.2 ± 0.1
24 mg/dl, $p<0.05$). The number of WBC was significantly less in the free CDDP group than the GM-CDDP
25 group ($3.6\pm 1.3 \times 10^3/\mu\text{l}$ vs. $9.9\pm 1.7 \times 10^3/\mu\text{l}$, $p<0.01$) and the control groups (Figure 4B).

26 27 **Histologic observation after the application of gelatin microspheres**

28 Figure 5 shows the histologic cross-sections of milky spots at greater omentum two days after receiving
29 gelatin microspheres. Microspheres and cancer cells were observed around the milky spots.

1 DISCUSSION

2
3 In the present study, we demonstrated that biodegradable GM-CDDP was effective in decreasing the
4 concentration of CDDP in the serum and kidney, resulting in a decrease in adverse systemic effects of
5 CDDP when delivered via gelatin microspheres intraperitoneally. We also showed that the administration of
6 GM-CDDP intraperitoneally in a model of peritoneal carcinomatosis in mice prolonged survival time
7 compared with that of free intraperitoneal administration of CDDP.

8 Gelatin is a biodegradable biomaterial that has been extensively used for medical, pharmaceutical, and
9 cosmetic applications. Hydrogels of different shapes can be formulated, and their feasibility as cell culture
10 substrates,¹⁷⁻¹⁹ cell scaffolds for tissue regeneration,²⁰⁻²² and carriers of growth factors or drugs²³⁻³⁰ have
11 been demonstrated experimentally. Based on the availability and ease of formulation of hydrogels, gelatin
12 was used as the hydrogel drug carrier both for hydrophilic anti-cancer agents and hydrophobic drugs such
13 as paclitaxel by using a micellar reaction.³¹

14 Gelatin is a protein with a random-coiled structure comprising 18 different types of linked amino acids.
15 There is a chelating interaction between the carboxyl groups and CDDP molecule, although the extent
16 depends on the polymer type.^{32, 33} According to our data, CDDP is released from the hydrogel based on the
17 hydrogel degradation. Through slower degradation of hydrogels, the in vivo volume of CDDP remains
18 large for a longer time period. In addition, the procedure of incorporating CDDP into the hydrogel is simple
19 without any loss of drug, while the CDDP dose can be changed only by altering the amount to be
20 incorporated. Cancer cells often secrete matrix metalloproteinases (MMP), such as collagenase and
21 gelatinase, which can proteolytically degrade gelatin microspheres to release the immobilized CDDP. With
22 cancer cells that secrete greater concentrations of endogenous MMPs, gelatin microspheres may release
23 CDDP more readily near the cancer site. Because of this feature, we believe it reasonable to use gelatin as a
24 drug vehicle for cancer treatment. It is likely that hydrogels with a greater extent of crosslinking will
25 degrade more slowly than those with a lesser crosslinking.¹⁶ In this study, the Gel 4 microspheres were
26 selected, because the microspheres with the longer time periods of CDDP release were more suitable for
27 our experiments (see appendix, online version only).

28 Previous work suggests that the maximum tolerated dose of CDDP for mice ranged from 5 to 10 mg/kg,
29 which corresponds to 100 μ g to 200 μ g per mouse.³⁴⁻³⁶ Also, prior work showed that even dose-dense
30 treatment with a maximum tolerated dose of cisplatin did not result in complete cancer eradication.³⁶ Our
31 preliminary experiment revealed that the tumors were already formed 48h after the implantation, and the
32 administration of CDDP at doses of less than 100 μ g did not show any significant anti-cancer effect against
33 the non-treatment group (data not shown). Even though the administrations were done at day1 and day4,
34 our results suggest that our model in this study was appropriate as a model of peritoneal carcinomatosis and
35 was difficult to treat with conventional dosage of CDDP, as the situation usually faced in clinical cases.

36 We believe that the side effects of free CDDP might have caused the first death (Figure 3B). The mouse
37 that died within 10 days did not exhibit any tumor nodules in the abdominal cavity at the autopsy. In
38 contrast, the other 5 mice that died more than 25 days after the treatment, demonstrated tumor nodules and
39 hemorrhagic ascites. We believe that some of the 5 mice may have died not only from the tumor but also of

1 the adverse effects of CDDP. We also thought that the initial high concentration of CDDP after the free
2 CDDP administration killed many cancer cells, but the rapid excretion of CDDP resulted in only a transient
3 effect of this drug to suppress cancer growth. In contrast to free CDDP administration, the GM-CDDP did
4 not increase the initial CDDP concentration due to the controlled release of CDDP. Even though the tumor
5 volumes of the two treatment groups were similar at day 10 (Figure 2 A & B), the survival time was
6 different between the two treatment groups.

7 Because the anti-cancer activity of CDDP depends on both the dose and exposure time,³⁷ sustained
8 release of CDDP is one of the superior anti-cancer effects of GM-CDDP; this release system appeared to
9 decrease the adverse effect of CDDP, allowing a more effective prolonged means of delivering CDDP
10 chemotherapy.

11 The microsphere release system can facilitate a safer and greater dose regimen of CDDP. The tolerance
12 study with weekly administration of GM-CDDP and free CDDP support this possibility (Figure 4). The
13 GM-CDDP significantly decreased not only the weight loss of mice, but also nephrotoxicity and
14 hematotoxicity. The GM-CDDP did not show an initial greater peak of CDDP concentration in the kidney
15 and serum (see appendix, online version only), which may explain the decrease in systemic toxicities
16 without affecting the anti-cancer effect of CDDP (Figure 2).

17 There have been reports about drug delivery systems with CDDP nano-particles, such as liposomes or
18 polymeric micelles, for intravenous administration on the basis of an enhanced permeability retention
19 effects¹⁴; some nano-particles however, showed greater systemic toxicity than free drugs.³⁸ This finding
20 may result from a much greater blood AUC of these types of drug delivery systems with CDDP nano-
21 particles. It is conceivable that the prolonged blood levels of drugs may increase the possibility of adverse
22 effects of anti-cancer agents. In addition, gelatin has a long history of clinical usage with established safety
23 in contrast to other polymers²³; the safety of some polymers as drug vehicles and their degradation products
24 in blood circulation are unknown clinically.

25 The lymphatics in the omental milky spots take part in the adsorption of various substances, including
26 cancer cells and micro-particles from the peritoneal cavity.^{39, 40} Moreover, the omental milky spots are sites
27 where cancer micrometastasis is initiated, even though the omentum appears normal on visual examination.
28 As shown in Figure 5, the particles of the GM-CDDP were localized in the milky spots of peritoneal cavity
29 by microscopy. Additionally, the microspheres were seen macroscopically along the greater omentum,
30 subphrenic area, pouch of Douglas, and hepatic portal region where tumor metastases are commonly
31 observed. This findings suggests that through the degradation of microspheres, a high concentration of
32 CDDP was released locally near the metastatic lesions, where the concentration of MMP, gelatinase, and
33 collagenase may be greater than in non-cancerous lesions.⁴¹ This system can be used as an active targeting
34 tool for peritoneal carcinomatosis.

35 Our study has several limitations; first, only animal experiments were carried out in this study. Second, the
36 number of animals was limited. Third, there might be an argument about the tumor weights measurement,
37 because it is impossible to excise all tumor cells. We removed as many tumor nodules as possible, and we
38 thought that we were able to measure accurately the weight of all of the tumors. We are planning to
39 examine other types of cancer, animals, and drugs, and then proceed to a clinical trial, which might have an

1 important impact on the treatment of patients with peritoneal carcinomatosis. We emphasize that this
2 gelatin hydrogel release system appears to be a promising tool for the patients with peritoneal
3 carcinomatosis.

1 Figure legend

2

3 Figure 1 Micrographs of gelatin microspheres.

4 (A) before crosslinking, (B) after crosslinking.

5 (C) Dry gelatin microspheres, and (D) after swelling.

6

7 Figure 2

8 (A)

9 Intraperitoneal findings of mice treated with GM-CDDP (a), free CDDP (b), GM without CDDP (c) and
10 PBS (non-treatment) (d). Arrows indicate the nodules of cancer growth.

11 (B)

12 The total weight of cancer of mice treated with GM-CDDP, free CDDP, GM without CDDP, and PBS
13 (non-treatment).

14 * $p < 0.001$, significant between the two groups. (n=5)

15

16 Figure 3

17 (A)

18 Body weight of mice during the first 2 weeks after the intraperitoneal administration of GM-CDDP, free
19 CDDP, GM without CDDP and PBS (non-treatment).

20 (B)

21 Survival of mice after the intraperitoneal administration of GM-CDDP, free CDDP, GM without CDDP
22 and mice without treatment (PBS).

23

24 Gelatin microspheres incorporating CDDP (○), free CDDP (△), GM without CDDP (●), and PBS group
25 (non-treatment) (□) (n=6)

26

27 Figure 4

28 (A)

29 Bodyweight of mice receiving weekly administration of GM-CDDP (○), free CDDP (△), GM without
30 CDDP (●) and PBS group (non-treatment) (□). (n=5)

31 (B)

32 Blood values of mice receiving weekly administration of GM-CDDP, free CDDP, GM without CDDP and
33 PBS.

34 * $p < 0.05$, significant between the four groups. (n=5)

35

36 Figure 5

37 Histologic section of milky spots in the mouse greater omentum, 1 day after the intraperitoneal
38 administration of gelatin microspheres.

39 (*) indicates gelatin microspheres, and arrows indicate cancer cells.

1 REFERENCES

- 2
- 3 1. Nissan A, Stojadinovic A, Garofalo A, Esquivel J, Piso P. Evidence-Based Medicine in the
4 Treatment of Peritoneal Carcinomatosis: Past, Present, and Future. *Journal of Surgical Oncology*.
5 2009;100:335-44.
- 6 2. Konishi M, Tabata Y, Kariya M, Suzuki A, Mandai M, Nanbu K, et al. In vivo anti-tumor effect
7 through the controlled release of cisplatin from biodegradable gelatin hydrogel. *Journal of*
8 *Controlled Release*. 2003;92:301-13.
- 9 3. Harries M, Gore M. Part I: Chemotherapy for epithelial ovarian cancer - treatment at first
10 diagnosis. *Lancet Oncology*. 2002;3:529-36.
- 11 4. Hundahl SA. Surgical quality in trials of adjuvant cancer therapy. *Journal of Surgical Oncology*.
12 2002;80:177-80.
- 13 5. Alberts DS, Liu PY, Hannigan EV, Otoole R, Williams SD, Young JA, et al. Intraperitoneal
14 cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous
15 cyclophosphamide for stage III ovarian cancer. *New England Journal of Medicine*. 1996;335:1950-
16 5.
- 17 6. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin
18 and paclitaxel in ovarian cancer. *New England Journal of Medicine*. 2006;354:34-43.
- 19 7. Ning SC, Yu N, Brown DM, Kanekal S, Knox SJ. Radiosensitization by intratumoral
20 administration of cisplatin in a sustained-release drug delivery system. *Radiotherapy and Oncology*.
21 1999;50:215-23.
- 22 8. Hirai M, Minematsu H, Hiramatsu Y, Kitagawa H, Otani T, Iwashita S, et al. Novel and simple
23 loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. *International*
24 *Journal of Pharmaceutics*. 2010;391:274-83.
- 25 9. Sasaki H, Niimi S, Akiyama M, Tanaka T, Hazato A, Kurozumi S, et al. Antitumor activity of
26 13,14-dihydro-15-deoxy-Delta(7)-prostaglandin-A(1)-methyl ester integrated into lipid
27 microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo. *Cancer Research*.
28 1999;59:3919-22.
- 29 10. Mizumura Y, Matsumura Y, Hamaguchi T, Nishiyama N, Kataoka K, Kawaguchi T, et al.
30 Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor
31 activity. *Japanese Journal of Cancer Research*. 2001;92:328-36.
- 32 11. Araki H, Tani T, Kodama M. Antitumor effect of cisplatin incorporated into polylactic acid
33 microcapsules. *Artificial Organs*. 1999;23:161-8.
- 34 12. Itoi K, Tabata CY, Ike O, Shimizu Y, Kuwabara M, Kyo M, et al. In vivo suppressive effects of
35 copoly(glycolic/L-lactic acid) microspheres containing CDDP on murine tumor cells. *Journal of*
36 *Controlled Release*. 1996;42:175-84.
- 37 13. Tokuda K, Natsugoe S, Shimada M, Kumano-hoso T, Baba M, Takao S, et al. Design and testing of
38 a new cisplatin form using a base material by combining poly-D,L-lactic acid and polyethylene
39 glycol acid against peritoneal metastasis. *International Journal of Cancer*. 1998;76:709-12.

- 1 14. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in
2 macromolecular therapeutics: a review. *Journal of Controlled Release*. 2000;65:271-84.
- 3 15. Hayashi K, Tabata Y. Preparation of stem cell aggregates with gelatin microspheres to enhance
4 biological functions. *Acta Biomaterialia*. 2011;7:2797-803.
- 5 16. Ogawa T, Akazawa T, Tabata Y. In Vitro Proliferation and Chondrogenic Differentiation of Rat
6 Bone Marrow Stem Cells Cultured with Gelatin Hydrogel Microspheres for TGF-beta 1 Release.
7 *Journal of Biomaterials Science-Polymer Edition*. 2010;21:609-21.
- 8 17. Hori Y, Inoue S, Hirano Y, Tabata Y. Effect of culture substrates and fibroblast growth factor
9 addition on the proliferation and differentiation of rat bone marrow stromal cells. *Tissue*
10 *Engineering*. 2004;10:995-1005.
- 11 18. Narita A, Takahara M, Ogino T, Fukushima S, Kimura Y, Tabata Y. Effect of gelatin hydrogel
12 incorporating fibroblast growth factor 2 on human meniscal cells in an organ culture model. *Knee*.
13 2009;16:285-9.
- 14 19. Takahashi Y, Yamamoto M, Tabata Y. Osteogenic differentiation of mesenchymal stem cells in
15 biodegradable sponges composed of gelatin and beta-tricalcium phosphate. *Biomaterials*.
16 2005;26:3587-96.
- 17 20. Hiraoka Y, Yamashiro H, Yasuda K, Kimura Y, Inamoto T, Tabata Y. In situ regeneration of adipose
18 tissue in rat fat pad by combining a collagen scaffold with gelatin microspheres containing basic
19 fibroblast growth factor. *Tissue Engineering*. 2006;12:1475-87.
- 20 21. Igai H, Chang SS, Gotoh M, Yamamoto Y, Misaki N, Okamoto T, et al. Regeneration of canine
21 tracheal cartilage by slow release of basic fibroblast growth factor from gelatin sponge. *Asaio*
22 *Journal*. 2006;52:86-91.
- 23 22. Okamoto T, Yamamoto Y, Gotoh M, Huang CL, Nakamura T, Shimizu Y, et al. Slow release of
24 bone morphogenetic protein 2 from a gelatin sponge to promote regeneration of tracheal cartilage
25 in a canine model. *Journal of Thoracic and Cardiovascular Surgery*. 2004;127:329-34.
- 26 23. Esaki J, Marui A, Tabata Y, Komeda M. Controlled release systems of angiogenic growth factors
27 for cardiovascular diseases. *Expert Opinion on Drug Delivery*. 2007;4:635-49.
- 28 24. Kikuchi T, Kubota S, Asaumi K, Kawaki H, Nishida T, Kawata K, et al. Promotion of bone
29 regeneration by CCN2 incorporated into gelatin hydrogel. *Tissue Engineering Part A*.
30 2008;14:1089-98.
- 31 25. Kimura Y, Tabata Y. Controlled Release of Stromal-Cell-Derived Factor-1 from Gelatin Hydrogels
32 Enhances Angiogenesis. *Journal of Biomaterials Science-Polymer Edition*. 2010;21:37-51.
- 33 26. Kushibiki T, Tomoshige R, Iwanaga K, Kakemi M, Tabata Y. Controlled release of plasmid DNA
34 from hydrogels prepared from gelatin cationized by different amine compounds. *Journal of*
35 *Controlled Release*. 2006;112:249-56.
- 36 27. Nitta N, Ohta S, Tanaka T, Takazakura R, Toyama T, Sonoda A, et al. An initial clinical study on
37 the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors. *European*
38 *Journal of Radiology*. 2009;71:519-26.
- 39 28. Ozeki M, Tabata Y. In vivo degradability of hydrogels prepared from different gelatins by various

- 1 cross-linking methods. *Journal of Biomaterials Science-Polymer Edition*. 2005;16:549-61.
- 2 29. Patel ZS, Yamamoto M, Ueda H, Tabata Y, Mikos AG. Biodegradable gelatin microparticles as
3 delivery systems for the controlled release of bone morphogenetic protein-2. *Acta Biomaterialia*.
4 2008;4:1126-38.
- 5 30. Tabata Y, Nagano A, Ikada Y. Biodegradation of hydrogel carrier incorporating fibroblast growth
6 factor. *Tissue Engineering*. 1999;5:127-38.
- 7 31. Lu Z, Yeh T-K, Wang J, Chen L, Lyness G, Xin Y, et al. Paclitaxel Gelatin Nanoparticles for
8 Intravesical Bladder Cancer Therapy. *Journal of Urology*. 2011;185:1478-83.
- 9 32. Schechter B, Pauzner R, Wilchek M, Arnon R. Cis-platinum (II) complexes of carboxymethyl-
10 dextran as potential antitumor agents. II. In vitro and in vivo activity.. *Cancer Biochemistry*
11 *Biophysics*. 1986;8:289-98.
- 12 33. Zhang JS, Imai T, Suenaga A, Otagiri M. Molecular-weight-dependent pharmacokinetics and
13 cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
14 *International Journal of Pharmaceutics*. 2002;240:23-31.
- 15 34. Imaizumi M, Kondo T, Taguchi T, Hattori T, Abe O, Kitano M, et al. A standardized method of
16 using nude mice for the in vivo screening of antitumor drugs for human tumors. *Surg Today-Jpn J*
17 *Surg*. 1993;23:412-9.
- 18 35. Molyneux G, Andrews M, Sones W, York M, Barnett A, Quirk E, et al. Haemotoxicity of
19 busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a
20 brief regimen of drug administration. *Cell Biol Toxicol*. 2011;27:13-40.
- 21 36. Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, et al. Tumor-initiating cells are
22 not enriched in cisplatin-surviving BRCA1; p53-deficient mammary tumor cells in vivo. *Cell*
23 *Cycle*. 2010;9:3780-91.
- 24 37. Kurihara N, Kubota T, Hoshiya Y, Otani Y, Watanabe M, Kumai K, et al. Antitumor activity of cis-
25 diamminedichloroplatinum (II) against human tumor xenografts depends on its area under the
26 curve in nude mice. *Journal of Surgical Oncology*. 1996;61:138-42.
- 27 38. Li S-D, Howell SB. CD44-Targeted Microparticles for Delivery of Cisplatin to Peritoneal
28 Metastases. *Molecular Pharmaceutics*. 2010;7:280-90.
- 29 39. Masataka S. Micrometastasis in Omental Milky Spots and Intraperitoneal Chemotherapy with
30 Carbon-adsorbed Mitomycin C (MMC-CH) Against Peritoneal Cancer Dissemination in Gastric
31 Cancer. *The Japanese journal of gastroenterological surgery* 27: 983-986, 1994.
- 32 40. Takahashi T, Hagiwara A, Shimotsuma M, Sawai K, Yamaguchi T. Prophylaxis and treatment of
33 peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated
34 carbon particles. *World Journal of Surgery*. 1995;19:565-9.
- 35 41. Otani Y, Okazaki I, Arai M, Kameyama K, Wada N, Maruyama K, et al. Gene expression of
36 interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. *Journal of*
37 *Gastroenterology*. 1994;29:391-7.

38
39








Figure 1

A



B





Figure 2

A



B





Figure 3

A



B




Figure 4




Figure5